[Retracted] Noscapine, an Emerging Medication for Different Diseases: A Mechanistic Review

Table 1

Evaluation of the effect of noscapine on cancer cells along with other first-line drugs.

Noscapine	Anticancer drug	Type of cancer	Growth inhibition (%)	In vivo or in vitro	Ref.
150–550 mg/kg/day	Doxorubicin (1.5 mg/kg)	Triple negative breast cancer (TNBC)	39.4%–82.9% synergistic interaction between noscapine and doxorubicin	In vitro MDA-mb-231 and MDA-mb-468 cells	[36]
300 mg/kg/day	Gemcitabine (30 mg/kg)	Non-small-cell lung cancer (NSCLC)	82.9 ± 4.5 synergistic interaction between noscapine and gemcitabine	In vitro H460 tumors	[32]
225 mg/kg twice per day	TMZ (5 mg/kg)	Glioblastoma multiforme TMZ-resistant	Noscapine increased survival in the orthotopic in vivo xenograft model of TMZ-resistant glioma.	In vitro U251 and A172 cells	[30]
100 mg/kg/day	Docetaxel (0.4 μM)	Triple negative breast cancer	30% increase in number of late apoptotic cells, synergistic interaction	In vitro MDA-mb-231 cells	[50]